FCSC Fibrocell Science Inc

2.08
0  0%
Previous Close 2.09
Open 2.07
Price To book 3.91
Market Cap 30.56M
Shares 14,693,000
Volume 35,151
Short Ratio 2.51
Av. Daily Volume 108,126

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued December 18, 2009. Approved June 22, 2011.
Laviv
Wrinkles
Phase 2 endpoints not met - June 2016
azficel-T
Chronic Dysphonia
Phase 1/2 initiation of dosing announced February 23, 2017. Phase 1 data due 3Q 2017.
FCX-007
Recessive dystrophic epidermolysis bullosa

SEC Filings

  1. SC 13D/A (Amend) - General statement of acquisition of beneficial ownership 17681995
  2. 8-K - Current report 17680334
  3. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17678842
  4. 8-K - Current report 17676828
  5. 8-K - Current report 17675940
  6. 424B5 - Prospectus (Rule 424(b)(5)) 17674903
  7. 424B5 - Prospectus (Rule 424(b)(5)) 17672397
  8. 8-K - Current report 17665364
  9. 8-K - Current report 17655150
  10. 8-K - Current report 17630790